Ivonescimab Plus Chemo Extends Squamous NSCLC Survival
- Study type
- Other
- Design
- News report on a trial conducted in China (trial type not stated in this record)
- Source
- Cancer Discovery · 2026
In plain words
In a study carried out in China, a new drug called ivonescimab, given with chemotherapy to people with the squamous type of advanced lung cancer, helped them live longer than the usual combination of immunotherapy and chemotherapy. It is not yet clear whether these results also apply to patients in other countries. Be sure to talk with your doctor about the right treatment for you.
Key results
Treatment arms and regimens
Ivonescimab (a bispecific anti-PD-1 and anti-VEGF antibody) plus chemotherapy. Dose details in the full text.
Combination of immunotherapy and chemotherapy. Drug and dose details in the full text.
Source of the regimen details: No dose details in this record; see the full text of the original trial paper
Doses are given for the information of specialists, as in this study’s protocol, and are not a prescription. Every drug must be prescribed by the treating physician for the individual patient.
Study population
Patients with advanced squamous non-small-cell lung cancer. Other inclusion criteria are not stated in this record.
Endpoints
This record reports only an improvement in overall survival. The primary and secondary endpoints are not specified in the record.
Safety and side effects
This record contains no information on adverse events.
Clinical significance and place in guidelines
This record is a short news report and does not give enough detail to judge its effect on clinical practice. The authors of the report noted uncertainty about whether the results apply to patients in other countries. The drug's approval status and its place in treatment guidelines should be checked separately.
Limitations
This record is only a short news report and gives no numerical data, sample size, design or adverse events. The trial was conducted only in China, and its generalisability to patients in other countries is uncertain.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.